SCHEMBL30575411

SCHEMBL30575411

CCCOc1ccc(S(=O)(=O)N2CCC([C@@H](CO[N+](=O)[O-])O[N+](=O)[O-])CC2)cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30575410 1.00 PDE5A (1.00) PDE5A
SCHEMBL20568340 1.00 PDE5A (1.00) PDE5A
SCHEMBL20569997 1.00 PDE5A (1.00) PDE5A
SCHEMBL20568337 1.00 PDE5A (1.00) PDE5A
SCHEMBL20570051 0.94 PDE5A (1.00) PDE5A
SCHEMBL22028288 0.94 PDE5A (1.00) PDE5A
SCHEMBL20567816 0.94 PDE5A (1.00) PDE5A
SCHEMBL22065426 0.92 PDE5A (0.88) PDE5A
SCHEMBL31268446 0.89 PDE5A (0.80) PDE5A
SCHEMBL31651386 0.89 PDE5A (0.82) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4486349-A1 TOPICAL COMPOSITIONS AND USES THEROF Topadur Pharma AG (CH) 2025-01-08 — — EP claimed
WO-2023166013-A9 TOPICAL COMPOSITIONS AND USES THEROF TOPADUR PHARMA AG (CH) 2024-05-23 — — WO claimed
WO-2023166013-A1 TOPICAL COMPOSITIONS AND USES THEROF TOPADUR PHARMA AG (CH) 2023-09-07 — — WO claimed
WO-2023167503-A1 TRANSDERMAL DOSAGE FORM, FOR PROMOTING LOCAL BLOOD FLOW, OF DUAL-ACTING PDE5 INHIBITOR/ORGANIC NITRATE ESTER 연세대학교 산학협력단 2023-09-07 — — WO claimed
EP-4486349-A1 TOPICAL COMPOSITIONS AND USES THEROF Topadur Pharma AG (CH) 2025-01-08 — — EP disclosed
CN-119095598-A Transdermal administration form of dual-effect PDE5 inhibitors/organic nitrates for enhancing local blood flow 延世大学校产学协力团 2024-12-06 — — CN disclosed
WO-2023166013-A9 TOPICAL COMPOSITIONS AND USES THEROF TOPADUR PHARMA AG (CH) 2024-05-23 — — WO disclosed
WO-2023166013-A1 TOPICAL COMPOSITIONS AND USES THEROF TOPADUR PHARMA AG (CH) 2023-09-07 — — WO disclosed
WO-2023167503-A1 TRANSDERMAL DOSAGE FORM, FOR PROMOTING LOCAL BLOOD FLOW, OF DUAL-ACTING PDE5 INHIBITOR/ORGANIC NITRATE ESTER 연세대학교 산학협력단 2023-09-07 — — WO disclosed
Send feedback